301 related articles for article (PubMed ID: 23503510)
1. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
Fialova B; Luzna P; Gursky J; Langova K; Kolar Z; Trtkova KS
Oncol Rep; 2016 Oct; 36(4):2365-74. PubMed ID: 27499010
[TBL] [Abstract][Full Text] [Related]
3. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
4. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Walton TJ; Li G; Seth R; McArdle SE; Bishop MC; Rees RC
Prostate; 2008 Feb; 68(2):210-22. PubMed ID: 18092350
[TBL] [Abstract][Full Text] [Related]
5. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
[TBL] [Abstract][Full Text] [Related]
6. Different effect of sodium butyrate on cancer and normal prostate cells.
Paskova L; Smesny Trtkova K; Fialova B; Benedikova A; Langova K; Kolar Z
Toxicol In Vitro; 2013 Aug; 27(5):1489-95. PubMed ID: 23524101
[TBL] [Abstract][Full Text] [Related]
7. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
9. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
Jarrard DF; Kinoshita H; Shi Y; Sandefur C; Hoff D; Meisner LF; Chang C; Herman JG; Isaacs WB; Nassif N
Cancer Res; 1998 Dec; 58(23):5310-4. PubMed ID: 9850055
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of the alcohol dehydrogenase 1B (ADH1B) and ADH1C genes by DNA methylation and histone deacetylation.
Dannenberg LO; Chen HJ; Tian H; Edenberg HJ
Alcohol Clin Exp Res; 2006 Jun; 30(6):928-37. PubMed ID: 16737450
[TBL] [Abstract][Full Text] [Related]
11. Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Trtkova K; Paskova L; Matijescukova N; Strnad M; Kolar Z
Neoplasma; 2010; 57(5):406-14. PubMed ID: 20568894
[TBL] [Abstract][Full Text] [Related]
12. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
13. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
[TBL] [Abstract][Full Text] [Related]
15. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells.
Zhu WG; Dai Z; Ding H; Srinivasan K; Hall J; Duan W; Villalona-Calero MA; Plass C; Otterson GA
Oncogene; 2001 Nov; 20(53):7787-96. PubMed ID: 11753657
[TBL] [Abstract][Full Text] [Related]
17. Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.
Wang X; Gao H; Ren L; Gu J; Zhang Y; Zhang Y
BMC Cancer; 2014 May; 14():308. PubMed ID: 24885368
[TBL] [Abstract][Full Text] [Related]
18. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Egger G; Aparicio AM; Escobar SG; Jones PA
Cancer Res; 2007 Jan; 67(1):346-53. PubMed ID: 17210717
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
